News

• Notice to Convene the Annual General Meeting of Genmab A/S
  02/24/2022 / 12:01 - GlobeNewswire
•  
• Genmab Publishes 2021 Annual Report
  02/16/2022 / 17:00 - GlobeNewswire
•  
• Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
  01/25/2022 / 12:30 - GlobeNewswire
•  
• Genmab Announces Financial Results for the First Nine Months of 2021
  11/10/2021 / 17:00 - GlobeNewswire
•  
• Genmab Improves its 2021 Financial Guidance
  11/04/2021 / 21:24 - GlobeNewswire
•  
• Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
  10/19/2021 / 12:29 - GlobeNewswire
•  
• Capital Increase in Genmab as a Result of Employee Warrant Exercise
  09/21/2021 / 20:22 - GlobeNewswire
•  
• Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
  09/20/2021 / 23:00 - GlobeNewswire
•  
• Genmab Announces Financial Results for the First Half of 2021
  08/11/2021 / 17:01 - GlobeNewswire
•  
• Major Shareholder Announcement
  07/21/2021 / 18:58 - GlobeNewswire
•  
• Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021
  07/21/2021 / 12:31 - GlobeNewswire
•  
• Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formulation, Including for the Treatment of Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
  06/22/2021 / 16:12 - GlobeNewswire
•  
• Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
  05/21/2021 / 15:08 - GlobeNewswire
•  
• Genmab Announces Financial Results for the First Quarter of 2021
  05/05/2021 / 17:01 - GlobeNewswire
•  
• Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
  04/20/2021 / 12:34 - GlobeNewswire